[1] |
SINGER A J, TASSIOPOULOS, KIRSNER R S. Evaluation and management of lower-extremity ulcers[J]. N Engl J Med, 2018, 378(3):302-303. DOI: 10.1056/NEJMc1715237.
|
[2] |
XU A, BALGOBIND A, STRUNK A,et al. Prevalence estimates for pyoderma gangrenosum in the United States:an age- and sex-adjusted population analysis[J]. J Am Acad Dermatol, 2020, 83(2):425-429. DOI: 10.1016/j.jaad.2019.08.001.
|
[3] |
LANGAN S M, GROVES R W, CARD T R,et al. Incidence,mortality,and disease associations of pyoderma gangrenosum in the United Kingdom:a retrospective cohort study[J]. J Invest Dermatol, 2012, 132(9):2166-2170. DOI: 10.1038/jid.2012.130.
|
[4] |
GOLDUST M, HAGSTROM E L, RATHOD D,et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J]. Expert Rev Clin Pharmacol, 2020, 13(2):157-161. DOI: 10.1080/17512433.2020.1709825.
|
[5] |
于孟学. 风湿科主治医生1053问[M]. 3版. 北京:中国协和医科大学出版社,2010:342-343.
|
[6] |
VELASCO M. Diagnostic and treatment of leg ulcers [J]. Actas Dermosifiliogr, 2011, 102(10):780-790. DOI: 10.1016/j.ad.2011.05.005.
|
[7] |
SINGER A J, TASSIOPOULOS, KIRSNER R S. Evaluation and management of lower-extremity ulcers[J]. N Engl J Med, 2018, 378(3):302-303. DOI: 10.1056/NEJMc1715237.
|
[8] |
FLETCHER J, ALHUSAYEN R, ALAVI A. Recent advances in managing and understanding pyoderma gangrenosum[J]. F1000Res, 2019, 8:2092. DOI: 10.12688/f1000research.19909.1.
|
[9] |
ALAVI A, FRENCH L E, DAVIS M D,et al. Pyoderma gangrenosum:an update on pathophysiology,diagnosis and treatment[J]. Am J Clin Dermatol, 2017, 18(3):355-372. DOI: 10.1007/s40257-017-0251-7.
|
[10] |
PATEL F, FITZMAURICE S, DUONG C,et al. Effective strategies for the management of pyoderma gangrenosum:a comprehensive review[J]. Acta Derm Venereol, 2015, 95(5):525-531. DOI: 10.2340/00015555-2008.
|
[11] |
GAMEIRO A, PEREIRA N, CARDOSO J C,et al. Pyoderma gangrenosum:challenges and solutions[J]. Clin Cosmet Investig Dermatol, 2015, 8:285-293. DOI: 10.2147/CCID.S61202.
|
[12] |
BINUS A M, QURESHI A A, LI V W,et al. Pyoderma gangrenosum:a retrospective review of patient characteristics,comorbidities and therapy in 103 patients[J]. Br J Dermatol, 2011, 165(6):1244-1250. DOI: 10.1111/j.1365-2133.2011.10565.x.
|
[13] |
XIA F D, LIU K, LOCKWOOD S,et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—a retrospective analysis[J]. J Am Acad Dermatol, 2018, 78(2):310-314.e1. DOI: 10.1016/j.jaad.2017.09.040.
|
[14] |
ASHCHYAN H J, BUTLER D C, NELSON C A,et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum[J]. JAMA Dermatol, 2018, 154(4):409-413. DOI: 10.1001/jamadermatol.2017.5978.
|
[15] |
HARBORD M, ANNESE V, VAVRICKA S R,et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2016, 10(3):239-254. DOI: 10.1093/ecco-jcc/jjv213.
|
[16] |
AHRONOWITZ I, HARP J, SHINKAI K. Etiology and management of pyoderma gangrenosum:a comprehensive review[J]. Am J Clin Dermatol, 2012, 13(3):191-211. DOI: 10.2165/11595240-000000000-00000.
|
[17] |
GOLDUST M, HAGSTROM E L, RATHOD D,et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J]. Expert Rev Clin Pharmacol, 2020, 13(2):157-161. DOI: 10.1080/17512433.2020.1709825.
|
[18] |
MAVERAKIS E, MA C, SHINKAI K,et al. Diagnostic criteria of ulcerative pyoderma gangrenosum:a Delphi consensus of international experts[J]. JAMA Dermatol, 2018, 154(4):461-466. DOI: 10.1001/jamadermatol.2017.5980.
|
[19] |
AHN C, NEGUS D, HUANG W. Pyoderma gangrenosum:a review of pathogenesis and treatment[J]. Expert Rev Clin Immunol, 2018, 14(3):225-233. DOI: 10.1080/1744666X.2018.1438269.
|
[20] |
BENNETT M L, JACKSON J M, JORIZZO J L,et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions[J]. Medicine (Baltimore), 2000, 79(1):37-46. DOI: 10.1097/00005792-200001000-00004.
|
[21] |
SARACINO A, KELLY R, LIEW D,et al. Pyoderma gangrenosum requiring inpatient management:a report of 26 cases with follow up[J]. Australas J Dermatol, 2011, 52(3):218-221. DOI: 10.1111/j.1440-0960.2011.00750.x.
|
[22] |
FEDERMAN G L, FEDERMAN D G. Recalcitrant pyoderma gangrenosum treated with thalidomide[J]. Mayo Clin Proc, 2000, 75(8):842-844. DOI: 10.4065/75.8.842.
|
[23] |
HECKER M S, LEBWOHL M G. Recalcitrant pyoderma gangrenosum:treatment with thalidomide[J]. J Am Acad Dermatol, 1998, 38(3):490-491. DOI: 10.1016/S0190-9622(98)70513-4.
|